Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Price Up 8.7% - What's Next?

Key Points

• Bayer shares jumped 8.7% to $13.915, although trading volume was approximately 95% below the stock’s average daily volume.
• Analyst sentiment improved, with Zacks Research upgrading the stock to “strong buy” and Deutsche Bank raising it to “buy.” The consensus rating is currently “Buy,” including two Strong Buy and five Buy ratings.
• Bayer exceeded quarterly expectations, reporting $0.29 in EPS versus the $0.23 estimate and $12.53 billion in revenue versus the $12.31 billion consensus. The company projects fiscal 2026 EPS of $1.200–$1.346.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) traded up 8.7% on Friday. The company traded as high as $13.93 and last traded at $13.9150. Approximately 55,379 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 1,062,721 shares. The stock had previously closed at $12.80.

Analysts Set New Price Targets

BAYRY has been the subject of several research reports. Zacks Research raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Friday, July 10th. Deutsche Bank Aktiengesellschaft raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Thursday, July 2nd. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy".

Bayer Aktiengesellschaft Trading Up 4.9%

The company has a current ratio of 1.04, a quick ratio of 0.67 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $55.14 billion, a P/E ratio of -27.51, a P/E/G ratio of 1.94 and a beta of 0.57. The firm has a 50-day moving average of $13.43 and a two-hundred day moving average of $12.52.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. The firm had revenue of $12.53 billion during the quarter, compared to analysts' expectations of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, analysts anticipate that Bayer Aktiengesellschaft will post 1.27 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.

Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women's health, oncology, hematology and specialty therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.